Back on April 19, the Peripheral and Central Nervous System Drugs Advisory Committee for the Food and Drug Administration met to discuss a new CBD oil solution drug application that would be used to treat rare forms of epilepsy.
The drug being discussed would treat seizures associated with Lennox-Gastaut syndrome or Dravet syndrome in patients two years of age and older.
According to meeting minutes provided by the advisory committee, a unanimous vote of 13-0 was made by various doctors and medical professionals that the benefit-risk profile of cannabidiol is favorable for the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
In testing the benefits of CBD oil on patients, there were 1,756 patients subjected to 323 controlled trials. Following the trials, doctors concluded that there was “substantial evidence of effectiveness of cannabidiol in the treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.”
Studies also showed that individuals taking this drug had 44% fewer seizures than those who where taking a placebo.
Multiple parents have said that giving CBD products to their young children with epilepsy have worked wonders. One family says that a girl’s life was saved due to CBD. She did not have epilepsy but did have another illness that caused seizures.
A study conducted in 2013 regarding children with epilepsy also yielded very positive results when the children were exposed to CBD treatment.
“Sixteen (84%) of the 19 parents reported a reduction in their child’s seizure frequency while taking cannabidiol-enriched cannabis. Of these, two (11%) reported complete seizure freedom, eight (42%) reported a greater than 80% reduction in seizure frequency, and six (32%) reported a 25 – 60% seizure reduction,” according to the report.
In one instance in Ireland, an 11-year-old boy who had severe epilepsy went at least 300 days without a seizure following a CBD treatment, according to a news report in The Independent.
But CBD is more than just a cure for seizures. CBD has also been linked to helping with other serious issues such as cancer, diabetes, and multiple sclerosis, while also assisting with less serious ailments like anxiety and sleep disorders.
It can also be used for skin issues and can support anti-aging.
CBD is available in various forms. There are CBD lotions, gel capsules, gummies, and tinctures.
CBD, unlike THC, does not make users high and Remedi’s CBD extracts come from hemp, which is a separate cannabis plant from marijuana. Industrial hemp is protected from federal law, thanks to a provision that was written into the 2014 U.S. Farm Bill.
Colorado is one of the many states that have legalized the industrial hemp production.
The Drug Enforcement Agency recently released an internal directive regarding the presence of cannabinoids in products and materials made from the cannabis plant where they clarified the already-familiar position that cannabinoids are not illegal of themselves and that it depends on the legal source of the product those cannabiniods are in – which determines if that product falls in or outside of the Controlled Substances Act.
The directive says: “Products and materials that are made from the cannabis plant and which fall outside the CSA definition of marijuana are not controlled under the CSA. Such products may accordingly be sold and otherwise distributed throughout the United States without restriction under the CSA or its implementing regulations. The mere presence of cannabinoids is not itself dispositive as to whether a substance is within the scope of the CSA; the dispositive question is whether the substance falls within the CSA definition of marijuana.”
As governments and medical professionals continue to tout the positive effects that CBD can have on patients, the consumer market will continue to grow. According to the Hemp Business Journal, the CBD market is projected to grow $2.1 billion by 2020.
Another report suggests the medical cannabis market in general, which could include more than just CBD, will grow to $33.4 billion by 2022.